David Yudovich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Yudovich has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Agatheeswaran Subramaniam
Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications - Alexandra Bäckström
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications - Jonas Larsson
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications - Kristijonas Žemaitis
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications - Christelle N. Prinz
Department of Physics, Division of Solid State Physics, Lund University, Lund, Sweden, Sweden
1 shared publication - Jun Chen
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
1 shared publication
Latest Publications
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (19) , 2151-2161
Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. Here, we report that inhibition of the epigenetic regulator lysine-specific histone demethylase 1A (LSD1) induces a rapid expansion of human cord blood–derived CD34+ cells and promotes in vitro propagation of long-term repopulating HSCs by preventing differentiation. The phenotype and molecular characteristics of cells treated with LSD1 inhibitors were highly similar to cells treated with UM171, an agent promoting expansion of HSCs through undefined mechanisms and currently being tested in clinical trials. Strikingly, we found that LSD1, as well as other members of the LSD1-containing chromatin remodeling complex CoREST, is rapidly polyubiquitinated and degraded upon UM171 treatment. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 depletion of the CoREST core member, RCOR1, resulted in expansion of CD34+ cells similar to LSD1 inhibition and UM171. Taken together, LSD1 and CoREST restrict HSC expansion and are principal targets of UM171, forming a mechanistic basis for the HSC-promoting activity of UM171.
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (19) , 2151-2161
Open AccessLysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. Here, we report that inhibition of the epigenetic regulator lysine-specific histone demethylase 1A (LSD1) induces a rapid expansion of human cord blood–derived CD34+ cells and promotes in vitro propagation of long-term repopulating HSCs by preventing differentiation. The phenotype and molecular characteristics of cells treated with LSD1 inhibitors were highly similar to cells treated with UM171, an agent promoting expansion of HSCs through undefined mechanisms and currently being tested in clinical trials. Strikingly, we found that LSD1, as well as other members of the LSD1-containing chromatin remodeling complex CoREST, is rapidly polyubiquitinated and degraded upon UM171 treatment. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 depletion of the CoREST core member, RCOR1, resulted in expansion of CD34+ cells similar to LSD1 inhibition and UM171. Taken together, LSD1 and CoREST restrict HSC expansion and are principal targets of UM171, forming a mechanistic basis for the HSC-promoting activity of UM171.
- Open Access
- 17 August 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (35) , 21267-21273
Efficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws
Significance: Primary stem cells are difficult to transfect, and their viability and function are impaired by traditional transfection methods. We show that nanostraws can be used to deliver RNA to primary human hematopoietic stem cells without any detectable negative effects. Nanostraw-treated cells show no alterations in gene expression and fully retain their proliferative capacity and their potential to regenerate blood cells of different lineages in vivo. This nonperturbative transfection method can benefit functional studies and clinical applications where minimal impact on stem cell function and viability is required.
- 17 August 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (35) , 21267-21273
Open AccessEfficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws
Significance: Primary stem cells are difficult to transfect, and their viability and function are impaired by traditional transfection methods. We show that nanostraws can be used to deliver RNA to primary human hematopoietic stem cells without any detectable negative effects. Nanostraw-treated cells show no alterations in gene expression and fully retain their proliferative capacity and their potential to regenerate blood cells of different lineages in vivo. This nonperturbative transfection method can benefit functional studies and clinical applications where minimal impact on stem cell function and viability is required.